Sign in
Taking peoplePhase 1/2

The Role of Melatonin as an Adjuvant Therapy in Childhood Pneumonia

Key facts

Who runs it
Mian Muhammad Hassan Ahmed
Where
Pakistan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 1/2
People taking part
60 people, planned
Started
May 2025
Planned end
Jan 2026
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Melatonin
Record updated
29 April 2025

Who can take part

Age
1 month to 12 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • 1 month to 12 years
  • Both genders
  • Patient diagnosed as having pneumonia or severe pneumonia according to WHO definition

Who cannot take part

  • Hospitalized within 14 days prior to the study
  • Currently taking melatonin
  • Active varicella or herpes simplex infection
  • Allergy to the study medication
  • Any non pneumonia acute medical illness which requires antibiotic treatment as per local standard of care
  • Significant co-morbid disease: lung, cardiac, immune, liver, endocrine, neurological or psychiatric
  • Galactose intolerance, the lapp-lactase deficiency or glucose-galactose malabsorption
  • Known TB exposure

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Pneumonia childhood

This trial is currently available in Pakistan.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this study is to compare the mean length of hospital stay between children with pneumonia receiving melatonin as an adjuvant therapy and those receiving standard of care alone.

Read full original descriptionShow less

The hypothesis is that combining oral melatonin with standard treatment can reduce the length of hospital stay as compared to standard of care alone.

The control group will receive standard treatment (antibiotic) while the intervention group will receive standard treatment plus melatonin for 14 days.

The 2 groups in the trial

  • Standard TreatmentNo study treatment, for comparison

    Standard treatment - Antibiotic such as ampicillin in a dose of 50mg//kg/dose x TDS

  • Adjuvant TherapyTreatment being tested

    Standard Treatment along with Melatonin @ 1 mg/dose in infants and 2.5 to 3mg/dose in children three times a day for 14 days

    Treatment: Melatonin

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT06949904, who can take part
Record updated
29 April 2025